Covered recipient · General Payments record
DANIEL T YEE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2022–2024
$456.80
- Reported across 20 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $395.94 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $81.87 | 3 |
| ABBVIE INC. | $60.41 | 2 |
| Lilly USA, LLC | $56.97 | 3 |
| Exact Sciences Corporation | $49.06 | 2 |
| Acerta Pharma LLC | $33.61 | 2 |
| Otsuka America Pharmaceutical, Inc. | $26.92 | 1 |
| PFIZER INC. | $23.54 | 1 |
| Abbott Laboratories | $22.15 | 1 |
| Sumitomo Pharma America, Inc. | $20.93 | 1 |
| Novo Nordisk AS | $20.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.15 | 12/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125247265 | CMS |
| ABBVIE INC. | $38.40 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106374248 | CMS |
| ABBVIE INC. | $22.01 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106374250 | CMS |
| Amgen Inc. | $26.43 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117420356 | CMS |
| Amgen Inc. | $23.44 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117420358 | CMS |
| Amgen Inc. | $32.00 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117420360 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.95 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104290190 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.66 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105323851 | CMS |
| Exact Sciences Corporation | $25.88 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114561274 | CMS |
| Exact Sciences Corporation | $23.18 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114561279 | CMS |
| Lilly USA, LLC | $20.06 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136134995 | CMS |
| Lilly USA, LLC | $20.89 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136114306 | CMS |
| Lilly USA, LLC | $16.02 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136134997 | CMS |
| Novo Nordisk Inc | $20.48 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096672929 | CMS |
| Otsuka America Pharmaceutical, Inc. | $26.92 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119007613 | CMS |
| PFIZER INC. | $23.54 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131107262 | CMS |
| Sumitomo Pharma America, Inc. | $20.93 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148938141 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.